Stroke
Conditions
Keywords
fNIRS, reproductibility, stroke, gait
Brief summary
Brain activation can be studied using the Functional Near InfraRed Spectroscopy (fNIRS). It was shown that CPF activation during walking and during dual task could be different in stroke patients and in healthy subjects. To date, fNIRS reliability is not completely established during walking and during dual task. Therefore, this study will examine the reproducibility of fNIRS parameters during simple walking and during dual task in healthy subjects and in stroke patients.
Detailed description
A fNIRS system will be used to measure the CPF activation. The subjects will walk at their preferred speed on 10 m 3 times and while doing a cognitive task (dual task) 3 times also (in a random order). The same test will be repeated five minutes later. The fNIRS system will be retired and the same test will be repeated 10 min later.
Interventions
All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
Sponsors
Centre Hospitalier Régional d'Orléans
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Healthy subjects, acute stroke patients, subacute stroke patients
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Acute stroke group, subacute stroke group, and control group: * Age 50 to 80 years * Affiliated with a social security plan * Able to walk 20 meters unassisted * Acute Stroke and Subacute Stroke Group: * Stroke onset less than 14 days (for the acute stroke group) or between 14 days and 6 months (for the subacute stroke group) * Stroke located in the left or right middle cerebral artery.
Exclusion criteria
* Acute stroke group, subacute stroke group, and control group: * Person under guardianship or curatorship * Refusal to sign informed consent * Known rheumatologic or cardiologic history * Medication that alters the vigilance and may affect walking (high dose psychotropic drugs, antispastic drugs). * Acute stroke group and subacute stroke group: * History of symptomatic stroke * Previous neurological disease limiting gait, aphasia or impaired cognitive function (mild cognitive dementia, Alzheimer's or Parkinson's disease) * Ambulatory functional category \< 3 * Control group: neurological medical history
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Oxyhemoglobin (HbO) variations during simple walking and during dual task | Day 0 | HbO will be measured by the NIR spectrometry technique continuously at rest and during walking. This technique allows to measure the variations of HbO concentration by measuring the variations of light absorption by the explored tissues. |
| Deoxyhemoglobin (HbR) variations during simple walking and during dual task | Day 0 | HbR will be measured by the NIR spectrometry technique continuously at rest and during walking. This technique allows to measure the variations of HbR concentration by measuring the variations of light absorption by the explored tissues. |
Secondary
| Measure | Time frame |
|---|---|
| Oxyhemoglobin (HbO) variations of subacute stroke patients | Day 0 |
| Deoxyhemoglobin (HbR) variations of subacute stroke patients | Day 0 |
| Oxyhemoglobin (HbO) variations of acute stroke patients | Day 0 |
| Deoxyhemoglobin (HbR) variations using different mathematical treatments. | Day 0 |
| Oxyhemoglobin (HbO) variations using different mathematical treatments. | Day 0 |
| Deoxyhemoglobin (HbR) variations of acute stroke patients | Day 0 |
Countries
France
Outcome results
None listed